Medigen Biotechnology Corp. engages in the research and development of new drugs and vaccines, cytotherapy, advanced nucleic acid testing, generic drugs, aesthetic medicine products, and the production and sale of vaccine-related products. It operates through the following segments: Nucleic Acid Testing, New Drug and Vaccine Research and Development, Cytotheraphy, Generic Drug, Aesthetic, Medicine Product, and Dietary Supplement. The company was founded on December 31, 1999 and is headquartered in Taipei, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company